ECOR electroCore

electroCore to Participate at 35th Annual Roth Conference

electroCore to Participate at 35th Annual Roth Conference

ROCKAWAY, NJ, March 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s Chief Strategy Officer, Joshua Lev, will participate in a fireside chat at the 35th Annual Roth Conference in Dana Point, California during March 12-14, 2023.



Roth Conference

Date: Tuesday, March 14, 2023

Time: 1:00 PM PT

Event: Fireside Chat



electroCore will also be available for one-on-one meetings during the conference. For more information or to schedule a meeting, please visit the conference page or email Investor Relations at .



About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.



For more information, visit .



Investors:

Rich Cockrell

CG Capital

404-736-3838



EN
09/03/2023

Underlying

ECORelectroCore

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE
Free
ECOR ELECTROCORE

Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore...

Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”) ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore™ Sapphire, electroCore’s non-invasive vagus nerve stimulator (nVNS), can be used as an adjunctive treatment of s...

January 21, 2026 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Provides Preliminary Full-Year 2025 Business Update; Expec...

electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 Revenue growth of approximately 26% over full-year 2024Cash, cash equivalents, and marketable securities (“Total Cash”) balance of approximately $11.6 million as of December 31, 2025 ROCKAWAY, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic tech...

January 20, 2026 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

TAC-STIM Demonstrates Significant Performance Improvements in Active-D...

TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced the publication of a peer reviewed paper titled “Non-Invasive Transcutaneous Vagal Nerve Stimulation Enhances Mood, Task Performance, and Learning in a High-Stress Military Training Environment” which will be presented at the Applied Human Factors and Ergonomics (AHFE2025) Conference on December 8, 2025. The paper pres...

December 2, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore to Participate at the Canaccord Genuity MedTech, Diagnosti...

electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The conference will take place in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel. Management will host one-on-one meetings throughout the day. Investors who wish to request a...

November 10, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Third Quarter 2025 Financial Results

electroCore Announces Third Quarter 2025 Financial Results Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities (“Total Cash”) of $13.2 million as of September 30, 2025  Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced financial results for t...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch